In re Neurontin Marketing and Sales Practices Litigation

TRANSFER ORDER

Now before the Panel are three separate motions encompassing a total of 27 actions that are listed on the attached Schedule A and are pending in sixteen districts as follows: six actions in the Eastern District of Louisiana; four actions in the District of Massachusetts; two actions each in the Eastern District of Arkansas, the Northern District of Florida, and the District of New Jersey; and one action each in the Southern District of Alabama, the Northern District of Georgia, the Southern District of Illinois, the Southern District of Indiana, the Western District of Louisiana, the District of Minnesota, the Southern District of Mississippi, the Southern District of New York, the Northern District of Ohio, the Western District of Tennessee, and the Northern District of Texas. 1 Pursuant to 28 U.S.C. § 1407, i) plaintiffs in one District of New Jersey action that originally moved for centralization in the District of New Jersey now move for centralization in the District of Massachusetts; ii) plaintiffs in two Eastern District of Louisiana actions move for centralization in their Louisiana district; and iii) common defendants Pfizer, Inc., Warner-Lambert Co., and Parke-Davis move for centraliza-tión in the Southern District of New York. No responding party opposes centralization, though respondents continue and expand upon the disagreement among mov-ants regarding the appropriate choice for transferee district. Thus, some respondents support one of the forums suggested in the three Section 1407 motions, while other respondents have expressed support for one of four other potential transferee districts: the Northern District of Illinois, the Southern District of Illinois, the District of New Jersey, and the Northern District of Ohio.

On the basis of the papers filed and hearing session held, the Panel finds that the actions in this litigation involve common questions of fact, and that centralization under Section 1407 in the District of Massachusetts will serve the convenience of the parties and witnesses and promote the just and efficient conduct of the litigation. All actions are purported class actions involving allegations that common defendants have engaged in the illegal promotion and sale of the drug Neurontin for “off-label” use. Centralization under Section 1407 is necessary in order to eliminate duplicative discovery, prevent inconsistent pretrial rulings (especially with respect to class certification matters), and conserve the resources of the parties, their counsel and the judiciary.

In concluding that the District of Massachusetts is an appropriate forum for this docket, we note that i) the district is where a False Claims Act qui tam action predicated on the same facts as those at issue in the MDL-1629 actions had been pending for eight years and had proceeded *1352 to a very advanced stage before being settled; and ii) the judge assigned to the constituent MDL-1629 Massachusetts actions is the same judge who presided over the qui tam action and is thus already thoroughly familiar with the issues of fact and law raised in the MDL-1629 actions.

IT IS THEREFORE ORDERED that, pursuant to 28 U.S.C. § 1407, the actions listed on Schedule A and pending outside the District of Massachusetts are transferred to that district and, with the consent of that court, assigned to the Honorable Patti B. Saris for coordinated or consolidated pretrial proceedings with the actions pending there and listed on Schedule A.

SCHEDULE A

MDL-1629 — In re Neurontin Marketing and Sales Practices Litigation

Southern District of Alabama

Gulf Distributing Holdings, LLC v.

Pfizer, Inc., C.A. No. 1:04-403

Eastern District of Arkansas Claudia Lang v. Pfizer, Inc., et al, C.A. No. 5:04-234

James Hope v. Pfizer, Inc., et al, C.A. No. 5:04-248

Northern District of Florida

Sylvia G. Hyman v. Pfizer, Inc., et al, C.A. No. 3:04-215

Clifford Eckenrode v. Pfizer, Inc., et al, C.A. No. 3:04-240

Northern District of Georgia Johnny Ray Meeks, et al. v. Pfizer, Inc., et al, C.A. No. 1:04-1781

Southern District of Illinois

Brenda Straddeck v. Pfizer, Inc., et al, C.A. No. 4:04-4106

Southern District of Indiana Gerald Smith v. Pfizer, Inc., et al, C.A. No. 1:04-1052

Eastern District of Louisiana

Emma B. Christina v. Pfizer, Inc., et al, C.A. No. 2:04-1450

Debra Mull, etc. v. Pfizer, Inc., et al, C.A. No. 2:04-1489

Maggie Dotty, et al. v. Pfizer, Inc., et al, C.A. No. 2:04-1547

Dianne Irene Hood v. Pfizer, Inc., et al., C.A. No. 2:04-1575

Joyce B. Duhe v. Pfizer, Inc., et al, C.A. No. 2:04-1591

Patricia Ann White v. Pfizer, Inc., C.A. No. 2:04-1712

Western District of Louisiana Annie D. Blevins v. Pfizer, Inc., C.A. No. 6:04-1162

District of Massachusetts The Guardian Life Insurance Co. of America v. Pfizer, Inc., et al, C.A. No. 1:04-10739

Aetna, Inc. v. Pfizer, Inc., et al, C.A. No. 1:04-10958

Harden Manufacturing Corp. v. Pfizer, Inc., et al, C.A. No. 1:04-10981

Teamsters Health & Welfare Fund of Philadelphia & Vicinity v. Pfizer Inc., et al, C.A. No. 1:04-10984

District of Minnesota

John Lerch v. Pfizer, Inc., et al, C.A. No. 0:04-3021

Southern District of Mississippi Mary Jane Gordon, et al. v. Pfizer, Inc., et al, C.A. No. 1:04-552

District of New Jersey ASEAJAFSCME Local 52 Health Benefits Trust, et al. v. Pfizer, Inc., et al, C.A. No. 2:04-2577

*1353 Julie K. Bakle v. Pfizer, Inc., et al., C.A. No. 2:04-2935

Southern District of Neiv York Lorraine Kopa v. Pfizer, Inc., et al., C.A. No. 1:04-4593

Northern District of Ohio Mary Lou Lienerth v. Pfizer, Inc., et al., C.A. No. 1:04-1161

Western District of Tennessee James Doyle v. Pfizer, Inc., et al., C.A. No. 2:04-2509

Northern District of Texas

Tammylee Willoz v. Pfizer, Inc., et al., C.A. No. 3:04-1234